{"cells":[{"metadata":{},"cell_type":"markdown","source":"# Import libraries"},{"metadata":{"trusted":true,"collapsed":true},"cell_type":"code","source":"!pip install scispacy","execution_count":2,"outputs":[{"output_type":"stream","text":"Collecting scispacy\n  Downloading scispacy-0.2.4.tar.gz (38 kB)\nRequirement already satisfied: spacy>=2.2.1 in /opt/conda/lib/python3.7/site-packages (from scispacy) (2.2.4)\nCollecting awscli\n  Downloading awscli-1.18.93-py2.py3-none-any.whl (3.2 MB)\n\u001b[K     |████████████████████████████████| 3.2 MB 10.0 MB/s eta 0:00:01\n\u001b[?25hCollecting conllu\n  Downloading conllu-3.0-py2.py3-none-any.whl (14 kB)\nRequirement already satisfied: numpy in /opt/conda/lib/python3.7/site-packages (from scispacy) (1.18.1)\nRequirement already satisfied: joblib in /opt/conda/lib/python3.7/site-packages (from scispacy) (0.14.1)\nCollecting nmslib>=1.7.3.6\n  Downloading nmslib-2.0.6-cp37-cp37m-manylinux2010_x86_64.whl (13.0 MB)\n\u001b[K     |████████████████████████████████| 13.0 MB 32.4 MB/s eta 0:00:01\n\u001b[?25hRequirement already satisfied: scikit-learn>=0.20.3 in /opt/conda/lib/python3.7/site-packages (from scispacy) (0.23.1)\nCollecting pysbd\n  Downloading pysbd-0.2.3-py3-none-any.whl (24 kB)\nRequirement already satisfied: cymem<2.1.0,>=2.0.2 in /opt/conda/lib/python3.7/site-packages (from spacy>=2.2.1->scispacy) (2.0.3)\nRequirement already satisfied: wasabi<1.1.0,>=0.4.0 in /opt/conda/lib/python3.7/site-packages (from spacy>=2.2.1->scispacy) (0.6.0)\nRequirement already satisfied: catalogue<1.1.0,>=0.0.7 in /opt/conda/lib/python3.7/site-packages (from spacy>=2.2.1->scispacy) (1.0.0)\nRequirement already satisfied: requests<3.0.0,>=2.13.0 in /opt/conda/lib/python3.7/site-packages (from spacy>=2.2.1->scispacy) (2.23.0)\nRequirement already satisfied: preshed<3.1.0,>=3.0.2 in /opt/conda/lib/python3.7/site-packages (from spacy>=2.2.1->scispacy) (3.0.2)\nRequirement already satisfied: tqdm<5.0.0,>=4.38.0 in /opt/conda/lib/python3.7/site-packages (from spacy>=2.2.1->scispacy) (4.45.0)\nRequirement already satisfied: setuptools in /opt/conda/lib/python3.7/site-packages (from spacy>=2.2.1->scispacy) (46.1.3.post20200325)\nRequirement already satisfied: murmurhash<1.1.0,>=0.28.0 in /opt/conda/lib/python3.7/site-packages (from spacy>=2.2.1->scispacy) (1.0.2)\nRequirement already satisfied: srsly<1.1.0,>=1.0.2 in /opt/conda/lib/python3.7/site-packages (from spacy>=2.2.1->scispacy) (1.0.2)\nRequirement already satisfied: blis<0.5.0,>=0.4.0 in /opt/conda/lib/python3.7/site-packages (from spacy>=2.2.1->scispacy) (0.4.1)\nRequirement already satisfied: plac<1.2.0,>=0.9.6 in /opt/conda/lib/python3.7/site-packages (from spacy>=2.2.1->scispacy) (1.1.3)\nRequirement already satisfied: thinc==7.4.0 in /opt/conda/lib/python3.7/site-packages (from spacy>=2.2.1->scispacy) (7.4.0)\nRequirement already satisfied: s3transfer<0.4.0,>=0.3.0 in /opt/conda/lib/python3.7/site-packages (from awscli->scispacy) (0.3.3)\nRequirement already satisfied: docutils<0.16,>=0.10 in /opt/conda/lib/python3.7/site-packages (from awscli->scispacy) (0.15.2)\nCollecting rsa<=3.5.0,>=3.1.2\n  Downloading rsa-3.4.2-py2.py3-none-any.whl (46 kB)\n\u001b[K     |████████████████████████████████| 46 kB 2.8 MB/s  eta 0:00:01\n\u001b[?25hRequirement already satisfied: PyYAML<5.4,>=3.10; python_version != \"3.4\" in /opt/conda/lib/python3.7/site-packages (from awscli->scispacy) (5.3.1)\nCollecting botocore==1.17.16\n  Downloading botocore-1.17.16-py2.py3-none-any.whl (6.3 MB)\n\u001b[K     |████████████████████████████████| 6.3 MB 40.9 MB/s eta 0:00:01\n\u001b[?25hRequirement already satisfied: colorama<0.4.4,>=0.2.5; python_version != \"3.4\" in /opt/conda/lib/python3.7/site-packages (from awscli->scispacy) (0.4.3)\nRequirement already satisfied: psutil in /opt/conda/lib/python3.7/site-packages (from nmslib>=1.7.3.6->scispacy) (5.7.0)\nRequirement already satisfied: pybind11>=2.2.3 in /opt/conda/lib/python3.7/site-packages (from nmslib>=1.7.3.6->scispacy) (2.5.0)\nRequirement already satisfied: scipy>=0.19.1 in /opt/conda/lib/python3.7/site-packages (from scikit-learn>=0.20.3->scispacy) (1.4.1)\nRequirement already satisfied: threadpoolctl>=2.0.0 in /opt/conda/lib/python3.7/site-packages (from scikit-learn>=0.20.3->scispacy) (2.1.0)\nRequirement already satisfied: importlib-metadata>=0.20; python_version < \"3.8\" in /opt/conda/lib/python3.7/site-packages (from catalogue<1.1.0,>=0.0.7->spacy>=2.2.1->scispacy) (1.6.0)\nRequirement already satisfied: idna<3,>=2.5 in /opt/conda/lib/python3.7/site-packages (from requests<3.0.0,>=2.13.0->spacy>=2.2.1->scispacy) (2.9)\nRequirement already satisfied: certifi>=2017.4.17 in /opt/conda/lib/python3.7/site-packages (from requests<3.0.0,>=2.13.0->spacy>=2.2.1->scispacy) (2020.4.5.2)\nRequirement already satisfied: urllib3!=1.25.0,!=1.25.1,<1.26,>=1.21.1 in /opt/conda/lib/python3.7/site-packages (from requests<3.0.0,>=2.13.0->spacy>=2.2.1->scispacy) (1.24.3)\nRequirement already satisfied: chardet<4,>=3.0.2 in /opt/conda/lib/python3.7/site-packages (from requests<3.0.0,>=2.13.0->spacy>=2.2.1->scispacy) (3.0.4)\nRequirement already satisfied: pyasn1>=0.1.3 in /opt/conda/lib/python3.7/site-packages (from rsa<=3.5.0,>=3.1.2->awscli->scispacy) (0.4.8)\nRequirement already satisfied: jmespath<1.0.0,>=0.7.1 in /opt/conda/lib/python3.7/site-packages (from botocore==1.17.16->awscli->scispacy) (0.10.0)\nRequirement already satisfied: python-dateutil<3.0.0,>=2.1 in /opt/conda/lib/python3.7/site-packages (from botocore==1.17.16->awscli->scispacy) (2.8.1)\nRequirement already satisfied: zipp>=0.5 in /opt/conda/lib/python3.7/site-packages (from importlib-metadata>=0.20; python_version < \"3.8\"->catalogue<1.1.0,>=0.0.7->spacy>=2.2.1->scispacy) (3.1.0)\nRequirement already satisfied: six>=1.5 in /opt/conda/lib/python3.7/site-packages (from python-dateutil<3.0.0,>=2.1->botocore==1.17.16->awscli->scispacy) (1.14.0)\nBuilding wheels for collected packages: scispacy\n  Building wheel for scispacy (setup.py) ... \u001b[?25ldone\n\u001b[?25h  Created wheel for scispacy: filename=scispacy-0.2.4-py3-none-any.whl size=35203 sha256=26e1303a97858756434444d441382e77dd082bfaa3360c22e2cdf2f3d805588d\n  Stored in directory: /root/.cache/pip/wheels/96/24/54/8c2bf5a6804275431a74bd256821500b3f2911d9ba8470a846\nSuccessfully built scispacy\nInstalling collected packages: rsa, botocore, awscli, conllu, nmslib, pysbd, scispacy\n  Attempting uninstall: rsa\n    Found existing installation: rsa 4.0\n    Uninstalling rsa-4.0:\n      Successfully uninstalled rsa-4.0\n  Attempting uninstall: botocore\n    Found existing installation: botocore 1.17.6\n    Uninstalling botocore-1.17.6:\n      Successfully uninstalled botocore-1.17.6\nSuccessfully installed awscli-1.18.93 botocore-1.17.16 conllu-3.0 nmslib-2.0.6 pysbd-0.2.3 rsa-3.4.2 scispacy-0.2.4\n","name":"stdout"}]},{"metadata":{"trusted":true,"collapsed":true},"cell_type":"code","source":"!pip install https://s3-us-west-2.amazonaws.com/ai2-s2-scispacy/releases/v0.2.4/en_core_sci_lg-0.2.4.tar.gz","execution_count":3,"outputs":[{"output_type":"stream","text":"Collecting https://s3-us-west-2.amazonaws.com/ai2-s2-scispacy/releases/v0.2.4/en_core_sci_lg-0.2.4.tar.gz\n  Downloading https://s3-us-west-2.amazonaws.com/ai2-s2-scispacy/releases/v0.2.4/en_core_sci_lg-0.2.4.tar.gz (500.6 MB)\n\u001b[K     |████████████████████████████████| 500.6 MB 6.9 kB/s  eta 0:00:01     |█████████                       | 141.8 MB 38.1 MB/s eta 0:00:10\n\u001b[?25hRequirement already satisfied: spacy>=2.2.1 in /opt/conda/lib/python3.7/site-packages (from en-core-sci-lg==0.2.4) (2.2.4)\nRequirement already satisfied: setuptools in /opt/conda/lib/python3.7/site-packages (from spacy>=2.2.1->en-core-sci-lg==0.2.4) (46.1.3.post20200325)\nRequirement already satisfied: murmurhash<1.1.0,>=0.28.0 in /opt/conda/lib/python3.7/site-packages (from spacy>=2.2.1->en-core-sci-lg==0.2.4) (1.0.2)\nRequirement already satisfied: requests<3.0.0,>=2.13.0 in /opt/conda/lib/python3.7/site-packages (from spacy>=2.2.1->en-core-sci-lg==0.2.4) (2.23.0)\nRequirement already satisfied: wasabi<1.1.0,>=0.4.0 in /opt/conda/lib/python3.7/site-packages (from spacy>=2.2.1->en-core-sci-lg==0.2.4) (0.6.0)\nRequirement already satisfied: catalogue<1.1.0,>=0.0.7 in /opt/conda/lib/python3.7/site-packages (from spacy>=2.2.1->en-core-sci-lg==0.2.4) (1.0.0)\nRequirement already satisfied: preshed<3.1.0,>=3.0.2 in /opt/conda/lib/python3.7/site-packages (from spacy>=2.2.1->en-core-sci-lg==0.2.4) (3.0.2)\nRequirement already satisfied: blis<0.5.0,>=0.4.0 in /opt/conda/lib/python3.7/site-packages (from spacy>=2.2.1->en-core-sci-lg==0.2.4) (0.4.1)\nRequirement already satisfied: tqdm<5.0.0,>=4.38.0 in /opt/conda/lib/python3.7/site-packages (from spacy>=2.2.1->en-core-sci-lg==0.2.4) (4.45.0)\nRequirement already satisfied: thinc==7.4.0 in /opt/conda/lib/python3.7/site-packages (from spacy>=2.2.1->en-core-sci-lg==0.2.4) (7.4.0)\nRequirement already satisfied: cymem<2.1.0,>=2.0.2 in /opt/conda/lib/python3.7/site-packages (from spacy>=2.2.1->en-core-sci-lg==0.2.4) (2.0.3)\nRequirement already satisfied: plac<1.2.0,>=0.9.6 in /opt/conda/lib/python3.7/site-packages (from spacy>=2.2.1->en-core-sci-lg==0.2.4) (1.1.3)\nRequirement already satisfied: numpy>=1.15.0 in /opt/conda/lib/python3.7/site-packages (from spacy>=2.2.1->en-core-sci-lg==0.2.4) (1.18.1)\nRequirement already satisfied: srsly<1.1.0,>=1.0.2 in /opt/conda/lib/python3.7/site-packages (from spacy>=2.2.1->en-core-sci-lg==0.2.4) (1.0.2)\nRequirement already satisfied: idna<3,>=2.5 in /opt/conda/lib/python3.7/site-packages (from requests<3.0.0,>=2.13.0->spacy>=2.2.1->en-core-sci-lg==0.2.4) (2.9)\nRequirement already satisfied: chardet<4,>=3.0.2 in /opt/conda/lib/python3.7/site-packages (from requests<3.0.0,>=2.13.0->spacy>=2.2.1->en-core-sci-lg==0.2.4) (3.0.4)\nRequirement already satisfied: urllib3!=1.25.0,!=1.25.1,<1.26,>=1.21.1 in /opt/conda/lib/python3.7/site-packages (from requests<3.0.0,>=2.13.0->spacy>=2.2.1->en-core-sci-lg==0.2.4) (1.24.3)\nRequirement already satisfied: certifi>=2017.4.17 in /opt/conda/lib/python3.7/site-packages (from requests<3.0.0,>=2.13.0->spacy>=2.2.1->en-core-sci-lg==0.2.4) (2020.4.5.2)\nRequirement already satisfied: importlib-metadata>=0.20; python_version < \"3.8\" in /opt/conda/lib/python3.7/site-packages (from catalogue<1.1.0,>=0.0.7->spacy>=2.2.1->en-core-sci-lg==0.2.4) (1.6.0)\nRequirement already satisfied: zipp>=0.5 in /opt/conda/lib/python3.7/site-packages (from importlib-metadata>=0.20; python_version < \"3.8\"->catalogue<1.1.0,>=0.0.7->spacy>=2.2.1->en-core-sci-lg==0.2.4) (3.1.0)\nBuilding wheels for collected packages: en-core-sci-lg\n  Building wheel for en-core-sci-lg (setup.py) ... \u001b[?25ldone\n\u001b[?25h  Created wheel for en-core-sci-lg: filename=en_core_sci_lg-0.2.4-py3-none-any.whl size=501343161 sha256=9e2984dc13c2ac3ea03d8c0cf05b3ec83bac0a012a6aa99203a71c5416090151\n  Stored in directory: /root/.cache/pip/wheels/06/a3/b5/bacce7d280488beaf177c3eadbe9f440244201544a0461f6f3\nSuccessfully built en-core-sci-lg\nInstalling collected packages: en-core-sci-lg\nSuccessfully installed en-core-sci-lg-0.2.4\n","name":"stdout"}]},{"metadata":{"_uuid":"8f2839f25d086af736a60e9eeb907d3b93b6e0e5","_cell_guid":"b1076dfc-b9ad-4769-8c92-a6c4dae69d19","trusted":true},"cell_type":"code","source":"import os\nimport re\nimport ast\nimport string\nimport numpy as np # linear algebra\nimport pandas as pd # data processing, CSV file I/O (e.g. pd.read_csv)\n\nimport spacy\nfrom spacy.vocab import Vocab\nimport scispacy\nimport en_core_sci_lg\nfrom scispacy.abbreviation import AbbreviationDetector\nfrom scispacy.umls_linking import UmlsEntityLinker\n\nfrom nltk import sent_tokenize\n\nfrom itertools import combinations\nfrom sklearn.metrics.pairwise import cosine_similarity\n\nfrom tqdm import tqdm\nfrom numba import jit # parallel processing","execution_count":1,"outputs":[]},{"metadata":{},"cell_type":"markdown","source":"# Initialize nlp and test vectors"},{"metadata":{"trusted":true,"collapsed":true},"cell_type":"code","source":"virus_words = pd.read_csv('/kaggle/input/virus-words/virus_words.txt',header=None)\nvirus_words[0]","execution_count":2,"outputs":[{"output_type":"execute_result","execution_count":2,"data":{"text/plain":"0                     COVID-19\n1                     COVID 19\n2                    2019-nCoV\n3                    2019 nCoV\n4                   SARS-CoV-2\n5                   SARS-CoV 2\n6                   SARS CoV-2\n7                   SARS CoV 2\n8                    SARS-CoV2\n9                   SARS-CoV19\n10                SARS-CoV2019\n11                    SARSCoV2\n12                   SARSCoV 2\n13                   SARSCoV19\n14                 SARSCoV2019\n15                   SARS CoV2\n16                  SARS Cov19\n17                 SARS Cov 19\n18               SARS CoV 2019\n19                SARS CoV2019\n20            2019 Coronavirus\n21    Coronavirus Disease 2019\n22            coronavirus 2019\n23         novel coronaviruses\n24                     covid19\nName: 0, dtype: object"},"metadata":{}}]},{"metadata":{"trusted":true,"collapsed":true},"cell_type":"code","source":"nlp = en_core_sci_lg.load(disable='parser')\nlinker = UmlsEntityLinker(resolve_abbreviations=True)\nnlp.add_pipe(linker)\nabbreviation_pipe = AbbreviationDetector(nlp)\nnlp.add_pipe(abbreviation_pipe)\n\nnew_vector = nlp(\n               \"\"\"Positive-sense single‐stranded ribonucleic acid virus, subgenus \n                   sarbecovirus of the genus Betacoronavirus. \n                   Also known as severe acute respiratory syndrome coronavirus 2, \n                   also known by 2019 novel coronavirus. It is \n                   contagious in humans and is the cause of the ongoing pandemic of \n                   coronavirus disease. Coronavirus disease 2019 is a zoonotic infectious \n                   disease.\"\"\").vector\n\nvocab = Vocab()\nfor virus_word in virus_words[0]:\n    nlp.vocab.set_vector(virus_word, new_vector)","execution_count":3,"outputs":[{"output_type":"stream","text":"/opt/conda/lib/python3.7/site-packages/sklearn/base.py:334: UserWarning: Trying to unpickle estimator TfidfTransformer from version 0.20.3 when using version 0.23.1. This might lead to breaking code or invalid results. Use at your own risk.\n  UserWarning)\n/opt/conda/lib/python3.7/site-packages/sklearn/base.py:334: UserWarning: Trying to unpickle estimator TfidfVectorizer from version 0.20.3 when using version 0.23.1. This might lead to breaking code or invalid results. Use at your own risk.\n  UserWarning)\n","name":"stderr"}]},{"metadata":{"trusted":true,"collapsed":true},"cell_type":"code","source":"# #parser or sentencizer must be enabled\n# doc = nlp(\"the most common symptoms for sars-cov-2 pneumonia at onset of illness were fever and cough, but some patients had presence of dyspnea at a median of 8 days all rights reserved. no reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. the copyright holder for this preprint this version posted june 3, 2020. . https://doi.org/10.1101/2020.06.01.20119032 doi: medrxiv preprint after onset of illness 9 . dyspnea, usually observed in severe patients with sars-cov-2 pneumonia 10 , may indicate the progression of disease with a low oxygenation index and a state of severe illness. however, up to now, the clinical course of sars-cov-2 pneumonia and risk factors for converting to severe cases remain unknown. this study was performed to investigate clinical characteristics of patients with severe sars-cov-2 pneumonia, and identify risk factors for those with mild to moderate disease who converted to severe cases. 120 patients (36 from ningbo first hospital and 84 from jingzhou central hospital) were included in this study, among which 62 were excluded and 58 were included in the final analysis. the results from this study showed that low peripheral blood lymphocyte count (<1Â·1Ã—10 9 /l) was an independent risk factor for patients converting to severe cases (or: 8Â·0, 95%ci: 1Â·5-41Â·8). with each reduction of 0Â·1Ã—10 9 /l in peripheral blood lymphocyte count, the or for converting to severe cases increased 28% (95%ci, 6%-54%). in addition, using of corticosteroids in mild to moderate patients with sars-cov-2 pneumonia was also associated with a reduced risk of converting to severe cases (or: 0Â·14, 95%ci: 0Â·02-0Â·80). lymphopenia was also observed in most patients with sars-cov infection during their course of illness 11, 12 . he et al believed that lymphopenia was a significant factor of sars-cov infection and lymphocyte counts may be useful in predicting the disease severity and clinical outcomes 12 . a recent study reported an absolute lymphopenia (lymphocyte count <1Â·0Ã—10 9 /l) in 63% of patients with sars-cov-2 pneumonia on admission. low levels of total lymphocyte counts were more marked in those patients in which infection resulted in death 10 . a possible cause for the lymphopenia may be that lymphocytes are directly infected and destroyed by sars-cov-2. however, this requires further study to confirm, as the cellular receptor for sars-cov-2 is angiotensin-converting enzyme 2 13 , which is not expressed on b or t lymphocytes 14 . therefore, depletion of lymphocytes may be secondary to the direct effect of the virus on the lymphocytes or the effect of various cytokine all rights reserved. no reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. the copyright holder for this preprint this version posted june 3, 2020. . https://doi.org/10.1101/2020.06.01.20119032 doi: medrxiv preprint mediated altered lymphocyte trafficking. since no antiviral treatment for sars-cov-2 infection has been proven to be effective, management of this disease remains clinically based and supportive 15 . considering that acute viral pneumonia is an important cause of acute lung injury (ali), the value of systematic corticosteroids in patients with sars-cov-2 infection is a focus of interest. this study showed patients who received low-to-moderate dose of systematic corticosteroids were less likely to convert to severe cases. in a report by chen et al 16 , the use of systematic corticosteroids in sars resulted in reduced mortality and a shorter hospitalization stay, and was not associated with significant secondary lower respiratory tract infection or other complications. however, it is well known that corticosteroid therapy is a double-edged sword 17, 18 . the immune response may be weak and consequently have more difficulty in eradicating the virus because of treatment with systematic corticosteroids 19 . further studies are urgently required to assess whether systematic corticosteroid treatment is beneficial in patients with sars-cov-2 pneumonia. some limitations of this study should be acknowledged. firstly, this was a retrospective study with a limited sample size, if the conclusion generalized is to be widely used, it would still need a prospective large-scale clinical validation. secondly, different varieties of traditional chinese medicine were administered to most patients, and the effectiveness and potential adverse effects of those drugs given remain largely unknown. thirdly, examinations of lymphocyte subsets were undertaken in this study, and in addition, total lymphocyte counts were not observed dynamically. despite the above limitations, we believe that our study has shown important and novel findings about the predictors of severe cases in mild to moderate patients with sars-cov-2 pneumonia. to our knowledge, this is the first study that has demonstrated that lymphocyte count is a useful predictor for severity of sars-cov-2 pneumonia. this may help clinicians more accurately predict prognosis, and triage all rights reserved. no reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. the copyright holder for this preprint this version posted june 3, 2020. . https://doi.org/10.1101/2020.06.01.20119032 doi: medrxiv preprint priorities to improve clinical outcomes. the findings from this study showed that low lymphocyte count (<1Â·1Ã—10 9 /l) in peripheral blood was an independent risk factor for patients who converted to severe cases. in addition, using of systematic corticosteroids in mild to moderate patients with sars-cov-2 pneumonia was associated with a reduced risk of converting to severe cases. further prospective studies are warranted to confirm these findings.\")\n# sents = [str(sent) for sent in doc.sents]\n# sents.index('despite the above limitations, we believe that our study has shown important and novel findings about the predictors of severe cases in mild to moderate patients with sars-cov-2 pneumonia.')\n# for sent in doc.sents:\n#     if str(sent) == 'despite the above limitations, we believe that our study has shown important and novel findings about the predictors of severe cases in mild to moderate patients with sars-cov-2 pneumonia.':\n#         print(sent.vector)\n#         v1 = sent.vector","execution_count":8,"outputs":[{"output_type":"error","ename":"ValueError","evalue":"[E030] Sentence boundaries unset. You can add the 'sentencizer' component to the pipeline with: nlp.add_pipe(nlp.create_pipe('sentencizer')) Alternatively, add the dependency parser, or set sentence boundaries by setting doc[i].is_sent_start.","traceback":["\u001b[0;31m---------------------------------------------------------------------------\u001b[0m","\u001b[0;31mValueError\u001b[0m                                Traceback (most recent call last)","\u001b[0;32m<ipython-input-8-536a9eadc0dd>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m\u001b[0m\n\u001b[1;32m      1\u001b[0m \u001b[0mdoc\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mnlp\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m\"the most common symptoms for sars-cov-2 pneumonia at onset of illness were fever and cough, but some patients had presence of dyspnea at a median of 8 days all rights reserved. no reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. the copyright holder for this preprint this version posted june 3, 2020. . https://doi.org/10.1101/2020.06.01.20119032 doi: medrxiv preprint after onset of illness 9 . dyspnea, usually observed in severe patients with sars-cov-2 pneumonia 10 , may indicate the progression of disease with a low oxygenation index and a state of severe illness. however, up to now, the clinical course of sars-cov-2 pneumonia and risk factors for converting to severe cases remain unknown. this study was performed to investigate clinical characteristics of patients with severe sars-cov-2 pneumonia, and identify risk factors for those with mild to moderate disease who converted to severe cases. 120 patients (36 from ningbo first hospital and 84 from jingzhou central hospital) were included in this study, among which 62 were excluded and 58 were included in the final analysis. the results from this study showed that low peripheral blood lymphocyte count (<1Â·1Ã—10 9 /l) was an independent risk factor for patients converting to severe cases (or: 8Â·0, 95%ci: 1Â·5-41Â·8). with each reduction of 0Â·1Ã—10 9 /l in peripheral blood lymphocyte count, the or for converting to severe cases increased 28% (95%ci, 6%-54%). in addition, using of corticosteroids in mild to moderate patients with sars-cov-2 pneumonia was also associated with a reduced risk of converting to severe cases (or: 0Â·14, 95%ci: 0Â·02-0Â·80). lymphopenia was also observed in most patients with sars-cov infection during their course of illness 11, 12 . he et al believed that lymphopenia was a significant factor of sars-cov infection and lymphocyte counts may be useful in predicting the disease severity and clinical outcomes 12 . a recent study reported an absolute lymphopenia (lymphocyte count <1Â·0Ã—10 9 /l) in 63% of patients with sars-cov-2 pneumonia on admission. low levels of total lymphocyte counts were more marked in those patients in which infection resulted in death 10 . a possible cause for the lymphopenia may be that lymphocytes are directly infected and destroyed by sars-cov-2. however, this requires further study to confirm, as the cellular receptor for sars-cov-2 is angiotensin-converting enzyme 2 13 , which is not expressed on b or t lymphocytes 14 . therefore, depletion of lymphocytes may be secondary to the direct effect of the virus on the lymphocytes or the effect of various cytokine all rights reserved. no reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. the copyright holder for this preprint this version posted june 3, 2020. . https://doi.org/10.1101/2020.06.01.20119032 doi: medrxiv preprint mediated altered lymphocyte trafficking. since no antiviral treatment for sars-cov-2 infection has been proven to be effective, management of this disease remains clinically based and supportive 15 . considering that acute viral pneumonia is an important cause of acute lung injury (ali), the value of systematic corticosteroids in patients with sars-cov-2 infection is a focus of interest. this study showed patients who received low-to-moderate dose of systematic corticosteroids were less likely to convert to severe cases. in a report by chen et al 16 , the use of systematic corticosteroids in sars resulted in reduced mortality and a shorter hospitalization stay, and was not associated with significant secondary lower respiratory tract infection or other complications. however, it is well known that corticosteroid therapy is a double-edged sword 17, 18 . the immune response may be weak and consequently have more difficulty in eradicating the virus because of treatment with systematic corticosteroids 19 . further studies are urgently required to assess whether systematic corticosteroid treatment is beneficial in patients with sars-cov-2 pneumonia. some limitations of this study should be acknowledged. firstly, this was a retrospective study with a limited sample size, if the conclusion generalized is to be widely used, it would still need a prospective large-scale clinical validation. secondly, different varieties of traditional chinese medicine were administered to most patients, and the effectiveness and potential adverse effects of those drugs given remain largely unknown. thirdly, examinations of lymphocyte subsets were undertaken in this study, and in addition, total lymphocyte counts were not observed dynamically. despite the above limitations, we believe that our study has shown important and novel findings about the predictors of severe cases in mild to moderate patients with sars-cov-2 pneumonia. to our knowledge, this is the first study that has demonstrated that lymphocyte count is a useful predictor for severity of sars-cov-2 pneumonia. this may help clinicians more accurately predict prognosis, and triage all rights reserved. no reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. the copyright holder for this preprint this version posted june 3, 2020. . https://doi.org/10.1101/2020.06.01.20119032 doi: medrxiv preprint priorities to improve clinical outcomes. the findings from this study showed that low lymphocyte count (<1Â·1Ã—10 9 /l) in peripheral blood was an independent risk factor for patients who converted to severe cases. in addition, using of systematic corticosteroids in mild to moderate patients with sars-cov-2 pneumonia was associated with a reduced risk of converting to severe cases. further prospective studies are warranted to confirm these findings.\"\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m----> 2\u001b[0;31m \u001b[0msents\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;34m[\u001b[0m\u001b[0mstr\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0msent\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;32mfor\u001b[0m \u001b[0msent\u001b[0m \u001b[0;32min\u001b[0m \u001b[0mdoc\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0msents\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m      3\u001b[0m \u001b[0msents\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mindex\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m'despite the above limitations, we believe that our study has shown important and novel findings about the predictors of severe cases in mild to moderate patients with sars-cov-2 pneumonia.'\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      4\u001b[0m \u001b[0;32mfor\u001b[0m \u001b[0msent\u001b[0m \u001b[0;32min\u001b[0m \u001b[0mdoc\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0msents\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      5\u001b[0m     \u001b[0;32mif\u001b[0m \u001b[0mstr\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0msent\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;34m==\u001b[0m \u001b[0;34m'despite the above limitations, we believe that our study has shown important and novel findings about the predictors of severe cases in mild to moderate patients with sars-cov-2 pneumonia.'\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n","\u001b[0;32m<ipython-input-8-536a9eadc0dd>\u001b[0m in \u001b[0;36m<listcomp>\u001b[0;34m(.0)\u001b[0m\n\u001b[1;32m      1\u001b[0m \u001b[0mdoc\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mnlp\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m\"the most common symptoms for sars-cov-2 pneumonia at onset of illness were fever and cough, but some patients had presence of dyspnea at a median of 8 days all rights reserved. no reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. the copyright holder for this preprint this version posted june 3, 2020. . https://doi.org/10.1101/2020.06.01.20119032 doi: medrxiv preprint after onset of illness 9 . dyspnea, usually observed in severe patients with sars-cov-2 pneumonia 10 , may indicate the progression of disease with a low oxygenation index and a state of severe illness. however, up to now, the clinical course of sars-cov-2 pneumonia and risk factors for converting to severe cases remain unknown. this study was performed to investigate clinical characteristics of patients with severe sars-cov-2 pneumonia, and identify risk factors for those with mild to moderate disease who converted to severe cases. 120 patients (36 from ningbo first hospital and 84 from jingzhou central hospital) were included in this study, among which 62 were excluded and 58 were included in the final analysis. the results from this study showed that low peripheral blood lymphocyte count (<1Â·1Ã—10 9 /l) was an independent risk factor for patients converting to severe cases (or: 8Â·0, 95%ci: 1Â·5-41Â·8). with each reduction of 0Â·1Ã—10 9 /l in peripheral blood lymphocyte count, the or for converting to severe cases increased 28% (95%ci, 6%-54%). in addition, using of corticosteroids in mild to moderate patients with sars-cov-2 pneumonia was also associated with a reduced risk of converting to severe cases (or: 0Â·14, 95%ci: 0Â·02-0Â·80). lymphopenia was also observed in most patients with sars-cov infection during their course of illness 11, 12 . he et al believed that lymphopenia was a significant factor of sars-cov infection and lymphocyte counts may be useful in predicting the disease severity and clinical outcomes 12 . a recent study reported an absolute lymphopenia (lymphocyte count <1Â·0Ã—10 9 /l) in 63% of patients with sars-cov-2 pneumonia on admission. low levels of total lymphocyte counts were more marked in those patients in which infection resulted in death 10 . a possible cause for the lymphopenia may be that lymphocytes are directly infected and destroyed by sars-cov-2. however, this requires further study to confirm, as the cellular receptor for sars-cov-2 is angiotensin-converting enzyme 2 13 , which is not expressed on b or t lymphocytes 14 . therefore, depletion of lymphocytes may be secondary to the direct effect of the virus on the lymphocytes or the effect of various cytokine all rights reserved. no reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. the copyright holder for this preprint this version posted june 3, 2020. . https://doi.org/10.1101/2020.06.01.20119032 doi: medrxiv preprint mediated altered lymphocyte trafficking. since no antiviral treatment for sars-cov-2 infection has been proven to be effective, management of this disease remains clinically based and supportive 15 . considering that acute viral pneumonia is an important cause of acute lung injury (ali), the value of systematic corticosteroids in patients with sars-cov-2 infection is a focus of interest. this study showed patients who received low-to-moderate dose of systematic corticosteroids were less likely to convert to severe cases. in a report by chen et al 16 , the use of systematic corticosteroids in sars resulted in reduced mortality and a shorter hospitalization stay, and was not associated with significant secondary lower respiratory tract infection or other complications. however, it is well known that corticosteroid therapy is a double-edged sword 17, 18 . the immune response may be weak and consequently have more difficulty in eradicating the virus because of treatment with systematic corticosteroids 19 . further studies are urgently required to assess whether systematic corticosteroid treatment is beneficial in patients with sars-cov-2 pneumonia. some limitations of this study should be acknowledged. firstly, this was a retrospective study with a limited sample size, if the conclusion generalized is to be widely used, it would still need a prospective large-scale clinical validation. secondly, different varieties of traditional chinese medicine were administered to most patients, and the effectiveness and potential adverse effects of those drugs given remain largely unknown. thirdly, examinations of lymphocyte subsets were undertaken in this study, and in addition, total lymphocyte counts were not observed dynamically. despite the above limitations, we believe that our study has shown important and novel findings about the predictors of severe cases in mild to moderate patients with sars-cov-2 pneumonia. to our knowledge, this is the first study that has demonstrated that lymphocyte count is a useful predictor for severity of sars-cov-2 pneumonia. this may help clinicians more accurately predict prognosis, and triage all rights reserved. no reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medrxiv a license to display the preprint in perpetuity. the copyright holder for this preprint this version posted june 3, 2020. . https://doi.org/10.1101/2020.06.01.20119032 doi: medrxiv preprint priorities to improve clinical outcomes. the findings from this study showed that low lymphocyte count (<1Â·1Ã—10 9 /l) in peripheral blood was an independent risk factor for patients who converted to severe cases. in addition, using of systematic corticosteroids in mild to moderate patients with sars-cov-2 pneumonia was associated with a reduced risk of converting to severe cases. further prospective studies are warranted to confirm these findings.\"\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m----> 2\u001b[0;31m \u001b[0msents\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;34m[\u001b[0m\u001b[0mstr\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0msent\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;32mfor\u001b[0m \u001b[0msent\u001b[0m \u001b[0;32min\u001b[0m \u001b[0mdoc\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0msents\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m      3\u001b[0m \u001b[0msents\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mindex\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m'despite the above limitations, we believe that our study has shown important and novel findings about the predictors of severe cases in mild to moderate patients with sars-cov-2 pneumonia.'\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      4\u001b[0m \u001b[0;32mfor\u001b[0m \u001b[0msent\u001b[0m \u001b[0;32min\u001b[0m \u001b[0mdoc\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0msents\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      5\u001b[0m     \u001b[0;32mif\u001b[0m \u001b[0mstr\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0msent\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;34m==\u001b[0m \u001b[0;34m'despite the above limitations, we believe that our study has shown important and novel findings about the predictors of severe cases in mild to moderate patients with sars-cov-2 pneumonia.'\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n","\u001b[0;32mdoc.pyx\u001b[0m in \u001b[0;36msents\u001b[0;34m()\u001b[0m\n","\u001b[0;31mValueError\u001b[0m: [E030] Sentence boundaries unset. You can add the 'sentencizer' component to the pipeline with: nlp.add_pipe(nlp.create_pipe('sentencizer')) Alternatively, add the dependency parser, or set sentence boundaries by setting doc[i].is_sent_start."]}]},{"metadata":{"trusted":true,"collapsed":true},"cell_type":"code","source":"# #parser or sentencizer must be enabled\n# doc = nlp('despite the above limitations, we believe that our study has shown important and novel findings about the predictors of severe cases in mild to moderate patients with sars-cov-2 pneumonia.')\n# for sent in doc.sents:\n#     print(sent.vector)\n#     v2 = sent.vector","execution_count":6,"outputs":[{"output_type":"stream","text":"[-0.0445595  -0.02728982  0.08810052 -0.0202131   0.0080669  -0.02247757\n -0.03786988 -0.00330973  0.00700686 -0.00102334  0.03151169 -0.1250888\n  0.05129229 -0.0407907   0.00537252 -0.05280348 -0.03947191 -0.13587129\n  0.01905933  0.09522764  0.06247263 -0.04573615 -0.01230669 -0.10526265\n  0.06168577  0.02632068  0.04959745 -0.09677126 -0.01858239  0.04353651\n  0.0020929  -0.11511589 -0.02223008 -0.04489174  0.13471201 -0.01841085\n  0.01872057  0.11095951 -0.1027195  -0.03613376 -0.06312553  0.01613808\n  0.04632265 -0.01602972  0.05645413 -0.04484621 -0.10683692 -0.11962598\n  0.02976297 -0.19699678  0.00736201  0.02555153 -0.03574163  0.05970762\n -0.03827594 -0.0290972  -0.05108489  0.0165926  -0.00119462 -0.07227673\n  0.0182394  -0.00743266 -0.00647731  0.07168672  0.05977864  0.03197805\n -0.00620746  0.08659254  0.06747445  0.04313469  0.0002598  -0.08746701\n -0.02293878  0.00041063 -0.01194189 -0.0242598   0.14824276  0.0164418\n  0.0280341   0.00734268  0.00241804 -0.10050812  0.01800495 -0.01929636\n -0.11344746  0.02844596 -0.07109266 -0.06068827  0.03806254 -0.00543832\n -0.03960153 -0.06636386 -0.08488315 -0.01139567  0.10026421  0.0399692\n  0.03770621 -0.02308433  0.0495826  -0.0659409   0.01625431 -0.03907663\n -0.07652944  0.02419509  0.02795583 -0.08296522  0.00187123  0.05918762\n  0.0326444   0.05091755  0.05512339 -0.02869122  0.02789889 -0.00196282\n  0.00174205 -0.06136646 -0.06645487 -0.01059226  0.04041229  0.00951559\n  0.07887453 -0.02270675 -0.08817022 -0.11464018 -0.01312347 -0.01493276\n -0.00989993 -0.07120423  0.00522985  0.00399599  0.03556311 -0.06517286\n -0.05133948 -0.03819029 -0.039557    0.14529078 -0.07550596  0.01966109\n -0.02955087  0.01764567 -0.07333788  0.0346853   0.0147181   0.17215952\n -0.09842309  0.00728482  0.04044588 -0.20783535  0.04882507  0.1190554\n  0.03172998 -0.00556459  0.14690576 -0.04969582  0.0790368   0.05423069\n  0.04777973 -0.0095719   0.0277327  -0.10681064 -0.00463541 -0.02677851\n  0.0360178   0.16288127 -0.05406647 -0.02446006 -0.05468268 -0.07438519\n  0.07464049 -0.05347127 -0.04118936 -0.08707324 -0.0031932  -0.10497136\n -0.09367891 -0.00093208 -0.03150383 -0.13856614  0.06503923 -0.01167535\n -0.04379991 -0.02238214 -0.05672513 -0.05140753  0.08575592  0.06869104\n -0.03038103  0.02420342 -0.05351262 -0.07789741 -0.04445877 -0.04593344\n -0.01867866  0.06190402 -0.06544617 -0.04809339  0.04593493  0.15665299\n -0.02198433 -0.12348834]\n","name":"stdout"}]},{"metadata":{"trusted":true},"cell_type":"code","source":"# if all([True for i,v in enumerate(v1) if v2[i]==v]):\n#     print('vectors are the same')","execution_count":7,"outputs":[{"output_type":"stream","text":"vectors are the same\n","name":"stdout"}]},{"metadata":{},"cell_type":"markdown","source":"# Define i/o paths"},{"metadata":{"_uuid":"d629ff2d2480ee46fbb7e2d37f6b5fab8052498a","_cell_guid":"79c7e3d0-c299-4dcb-8224-4455121ee9b0","trusted":true},"cell_type":"code","source":"input_data_path = '/kaggle/input/v31-claims/'\ninput_data_file = 'claims_flag_each_cord_uid_200620.csv'\n\nmetadata_file_path = '/kaggle/input/CORD-19-research-challenge/'\nmetadata_file = 'metadata.csv'","execution_count":4,"outputs":[]},{"metadata":{},"cell_type":"markdown","source":"# Read and process data"},{"metadata":{"trusted":true,"collapsed":true},"cell_type":"code","source":"metadata = pd.read_csv(metadata_file_path+metadata_file)\nmetadata = metadata[['cord_uid','publish_time','title']]","execution_count":5,"outputs":[{"output_type":"stream","text":"/opt/conda/lib/python3.7/site-packages/IPython/core/interactiveshell.py:3063: DtypeWarning: Columns (5,6,13,14,16) have mixed types.Specify dtype option on import or set low_memory=False.\n  interactivity=interactivity, compiler=compiler, result=result)\n","name":"stderr"}]},{"metadata":{"trusted":true},"cell_type":"code","source":"input_data = pd.read_csv(input_data_path+input_data_file)\nno_claims_cord_uid = set(input_data.loc[input_data.claim_flag==0,'cord_uid'])\\\n                               - set(input_data.loc[input_data.claim_flag==1,'cord_uid'])\n\nprint('No of unique sentences in claims:',input_data.loc[input_data.claim_flag==1,'claims'].nunique())\nprint('No of rows in claims:',len(input_data.loc[input_data.claim_flag==1,:]))\nprint('\\n')\nprint('Total no of papers:',input_data.cord_uid.nunique())\nprint('Papers with claims:',input_data.loc[input_data.claim_flag==1,'cord_uid'].nunique())\nprint('Papers with no claims:',len(no_claims_cord_uid))","execution_count":7,"outputs":[{"output_type":"stream","text":"No of unique sentences in claims: 4559\nNo of rows in claims: 4781\n\n\nTotal no of papers: 2564\nPapers with claims: 1819\nPapers with no claims: 745\n","name":"stdout"}]},{"metadata":{"trusted":true},"cell_type":"code","source":"#For papers with no claims, tokenize to sentences\nclaims_data = input_data.loc[input_data.claim_flag==1,:].copy().reset_index(drop=True)\nno_claims_data = input_data.loc[input_data.cord_uid.isin(no_claims_cord_uid),:].copy().reset_index(drop=True)\n\ndict = {}\nk = 0\n\nfor i,text in enumerate(no_claims_data.text):\n    for sent in sent_tokenize(text):\n        dict[k] = {'cord_uid':no_claims_data.cord_uid[i],\\\n                   'section':no_claims_data.section[i],\\\n                   'text':no_claims_data.text[i],\\\n                   'drug_terms_used':no_claims_data.drug_terms_used[i],\\\n                   'claims':sent}\n        k = k + 1\n        \nno_claims_data = pd.DataFrame.from_dict(dict, \"index\")\nprint('Total rows for papers with no claims:',len(no_claims_data))","execution_count":26,"outputs":[{"output_type":"stream","text":"Total rows for papers with no claims: 19922\n","name":"stdout"}]},{"metadata":{"trusted":true},"cell_type":"code","source":"print('Papers with at least 1 claim in abstract section:',claims_data.loc[claims_data.section.str.lower()=='abstract','cord_uid'].nunique())","execution_count":27,"outputs":[{"output_type":"stream","text":"Papers with at least 1 claim in abstract section: 527\n","name":"stdout"}]},{"metadata":{"trusted":true,"collapsed":true},"cell_type":"code","source":"claims_data.section.unique()","execution_count":14,"outputs":[{"output_type":"execute_result","execution_count":14,"data":{"text/plain":"array(['Abstract', 'CONCLUSION', 'CONCLUSION:', 'Discussion',\n       'Conclusion', 'DISCUSSION', 'CONCLUSIONS',\n       'Factors That Put People With Schizophrenia at Elevated Risk of Acquiring COVID-19 and of Experiencing Poor Outcomes',\n       'Conclusions', 'Discussion and Conclusion', '4. Conclusions',\n       '8. Conclusions', 'Results and Discussion',\n       'Complications, treatment and clinical outcomes during hospitalization and follow-up 296',\n       '4. Discussion', '5. Conclusions', 'CONCLUSION 40',\n       'Table: Demographics, clinical characteristics at admission, treatment, and outcomes of five patients with HIV and COVID-19',\n       'Results and discussion', 'Results and Discussion.',\n       'RESULTS AND DISCUSSION', 'Added value of this study',\n       'The proposed D-peptide ::: Discussion and conclusions',\n       'The proposed L-peptide ::: Discussion and conclusions',\n       '| DISCUSSION', 'Discussion and conclusions', 'Discussion:',\n       'DISCUSSION AND CONCLUSIONS',\n       'Outcomes of cancer patients with a SARS-CoV-2 infection ::: Results',\n       'Molecular docking ::: Results and discussion',\n       'Sequence and structural analyses ::: Results and discussion',\n       'In older men with age-related diseases, the aging-dependent reduction in ACE2 activity worsens SARS-CoV-2 infection outcomes',\n       'In older men, immune senescence worsens COVID-19 infection outcomes',\n       'Effectiveness of some anti-HIV/AIDS drugs for 2019-nCoV ::: Discussions',\n       'Partition coefficient ::: Discussions',\n       '3.10. Limitations ::: 3. Results and Discussion',\n       '3.3. Identification of the VDR and HIF1a Genes as Putative Repressors of the ACE2 Expression ::: 3. Results and Discussion',\n       '3.4. GSEA Identify Estradiol and Quercetin as Putative Candidate Coronavirus Infection Mitigation Agents ::: 3. Results and Discussion',\n       '3.5. Confirmation of the Estradiol and Quercetin Activities as Potential Candidate Coronavirus Infection Mitigation Agents ::: 3. Results and Discussion',\n       '3.6. Inference of Potential Interference of the Quercetin, Vitamin D, and Estradiol with Functions of SARS-CoV-2 Proteins in Human Cells ::: 3. Results and Discussion',\n       '3.7. Potential Mechanisms Affecting Gene Expression Inferred from Transgenic Mouse Models and Observed in Pathophysiologically and Therapeutically Relevant Mouse and Human Cells ::: 3. Results and Discussion',\n       '3.8. Is Vitamin D Deficiency a Potential Risk Factor for Increased Disease Severity in Older Adults and Elderly Individuals? ::: 3. Results and Discussion',\n       '3.9. Clinical and Experimental Observations Appear Highly Compatible with the Results of Genomic-Guided Mapping of COVID-19 Targets in Human Cells ::: 3. Results and Discussion',\n       'Additional experiments and conclusions',\n       'Assay Validation ::: Results and Discussion',\n       'Effects of exposure time, humidity, and ozone concentration on virus inactivation ::: Results and Discussion',\n       'Rationale: IVIG might help to improve the outcome of patients with COVID-19',\n       'Rationale: IVIG might help to improve the outcome of patients with COVID-19 ::: Intravenous immunoglobulins (IVIG) ::: Passive immunization',\n       'Limitations ::: Discussion', 'Biological interpretation',\n       '4.4. Comorbidities and Liver Injury in COVID-19 Patients ::: 4. Discussion',\n       '4.5. SARS-CoV-1 and Liver Injury ::: 4. Discussion', 'discussion',\n       'Discussion.',\n       'Head and Neck Surgery ::: Specific Protective Measures in Otolaryngologic Surgery ::: Discussion',\n       'Diagnostics at the Bedsideto SupportTreatmentand Care ::: DISCUSSION',\n       'Monitoring NMB ::: DISCUSSION',\n       'Monitoring Sedationvia Processed EEG ::: DISCUSSION',\n       'SUMMARY AND DISCUSSION',\n       'Comparison of patients with COVID-19 and patients with influenza ::: Discussion',\n       'Discussion 1',\n       'Co-expression of SARS-CoV-2 entry factors in the adult human ocular surface epithelium and presence of inflammatory programs in the putative target cells ::: Results and discussion',\n       'Conclusions:',\n       'Identification of the top hits ::: Results and discussion',\n       'Consequences of the hypothesis/Conclusion and Implications',\n       'Advantages of the newly developed PBPK model ::: Discussion',\n       'A rare mutation, D839Y/E, recently observed in a SARS2 strain from Europe contributes to stabilizing the interaction with TCR. ::: RESULTS AND DISCUSSION',\n       'Further examination of the motif near PRRA reveals close structural similarity to the SEB superantigen as well as sequence similarities to neurotoxins and a viral SAg. ::: RESULTS AND DISCUSSION',\n       'Conclusion and future perspective',\n       'Comparison with other studies ::: Discussion',\n       'Conclusion and policy implications ::: Discussion',\n       'Complicating phase ::: Discussion',\n       'Propagating phase ::: Discussion',\n       'Drugs binding to SARS-CoV-2 RdRp ::: Results and discussion',\n       'DISCUSSION 288', 'AbsTrACT', 'DIsCussIOn',\n       'Deubiquitinating Activities of SARS-CoV-2 PLpro ::: Discussion',\n       '■ DISCUSSION',\n       'Additional docking simulations for hit compounds ::: Results and Discussion',\n       'Discussion and conclusion',\n       'Preliminary data on outcomes of SARS-CoV-2 infection in a Spanish single center cohort of kidney recipients',\n       'Discussion 247',\n       'ACE2 plasma concentrations and use of RAAS inhibitors ::: Discussion',\n       'Results and discussion:', 'Concluding remarks',\n       'Therapeutic implications: tocilizumab & the risk of hasty conclusions',\n       'Binding free energy analysis ::: Results and discussion',\n       'POTENTIAL THERAPEUTIC TARGETS AND CONCLUSION (SEE FIGURE 2)',\n       'Potential Therapeutic Targets and Conclusion (See #!start#FIGURE 2#!sep#F2#!sep#fig#!end#)',\n       '3. Discussion',\n       'Performance of the concentration method ::: Results and discussion',\n       'Future Directions ::: Discussion',\n       'Localized impairment to SARS-CoV-2 S glycan maturation ::: Results and discussion',\n       'Perspectives ::: Results and discussion',\n       'SLE and COVID-19 ::: Discussion',\n       'Conclusion and future prospects', 'Morgue and PPE ::: DISCUSSION',\n       'Outstanding questions and concluding remarks',\n       'Laboratory findings ::: Discussion',\n       'Conclusion and future research', 'Discussion and conclusion.',\n       'Hematology ::: Discussion', 'Rheumatology ::: Discussion',\n       'Conclusions and Perspectives',\n       'Docking studies ::: Results and discussion',\n       'Discussion and Conclusions', '6. Discussion and Conclusions',\n       'Discussion: Implications for COVID-19', 'Concluding Statement',\n       'Nucleocapsid protein (N) ::: Results and Discussion',\n       '3) Discussion',\n       'Protein structure and validation ::: Results and Discussion',\n       'Sequence alignment analysis ::: Results and Discussion',\n       'MD Simulation ::: Results and discussion',\n       'Virtual screening ::: Results and discussion',\n       '2.2. Virtual Screening Procedures ::: 2. Results and Discussion',\n       '2.3. Final Compound Selection ::: 2. Results and Discussion',\n       'The GTNGTKR motif in binding protein receptors ::: Results and discussion',\n       'The GTNGTKR motif in binding sugar receptors ::: Results and discussion',\n       'Predicted Inhibitory Efficiency ::: Results and Discussion',\n       'Protein–Drug Hydrogen Bonding ::: Results and Discussion',\n       'Solvent Accessibility in the 3CLpro Active Site ::: Results and Discussion',\n       '■ CONCLUSIONS', 'Summary and conclusions', 'Act V (conclusion)',\n       'Discussion ::: Results', 'Conclusions and future directions',\n       'Pathological mechanism of anti-NCP TCM ::: Discussion',\n       '5.2. Perceptions of and Attitudes toward Game Meat ::: 5. Discussion',\n       'Molecular dynamics simulation ::: Results and discussion',\n       'The binding affinities of the ligands into ACE2 active site ::: Molecular docking simulation ::: Results and discussion',\n       'Discussion 598',\n       'Clinical outcome in solid organ transplant recipients with COVID-19: A single-center experience',\n       'Conclusion:', '6.Conclusions', 'Conclusions. ::: ',\n       'Principal component analysis ::: Results and discussion',\n       'Concluding Remarks',\n       'Poor clinical outcomes for patients with cancer during the COVID-19 pandemic',\n       'Antiviral properties of herbs and compounds against the SARS-CoV ::: Discussion',\n       'Conclusion and perspectives',\n       'Herbal medicine and the inhibition/blockade of the coronavirus-host target protein pathways ::: The SARS-CoV and host protein pathways ::: Discussion',\n       'MSC therapy: analysis of outcomes', '4. Concluding Remarks',\n       'Free binding energy analysis/Poisson\\u2009−\\u2009Boltzmann surface area (MM-PBSA) ::: Results and discussion',\n       'Hydrogen bond analysis ::: Results and discussion',\n       'MD Simulations ::: Results and discussion',\n       'SASA analysis ::: Results and discussion', 'Discussion 348',\n       'DISCUSSIONS', 'Discussions',\n       'LDA should support the gene-novelty theory about the abundance of gene overlap in viruses ::: Discussion',\n       'The new variants of apoptin and X protein are a useful benchmark for experimental studies ::: Discussion',\n       'DISCUSSION:',\n       \"Determination of the inactivation agent's cytotoxicity ::: Results and discussion\",\n       'Concluding Remarks ::: Main Text',\n       'Discussion and evaluation ::: Implementation and results',\n       'Liver transplantation and the COVID‐19 outbreak ::: DISCUSSION',\n       'Case Discussion', 'Case discussion ::: Discussion',\n       'Hybrid model ::: Discussion',\n       'Recommendations for workup and management of delirium in COVID-19 ::: Discussion',\n       'Discussion 194', '4. Conclusions ', '| RESULTS AND DISCUSSION',\n       'Review of clinical research databases and response to the questionnaire ::: Development of the common minimal outcome set',\n       'III. RESULTS AND DISCUSSION', 'Conclusions ::: Discussion',\n       '3.1.7. Madagascar ::: 3.1. East Africa ::: 3. Results and Discussion',\n       '3.5.4. South Africa ::: 3.5. Southern Africa ::: 3. Results and Discussion',\n       'Conclusion and Future perspectives to control to SARS-CoV-2 pandemic',\n       'Conclusion and Discussion',\n       '2.1. Radical Scavenging Activities ::: 2. Results and Discussion',\n       '2.2. Anti-Inflammatory Activities ::: 2. Results and Discussion',\n       '2.3. Anti-Hyperglycemic Activity ::: 2. Results and Discussion',\n       '2.4. Anti-Coagulant Activity ::: 2. Results and Discussion',\n       'AbstrAct', 'Consequences of the hypothesis and discussion',\n       'Discussion 206',\n       'Environmental impact ::: Results and discussion',\n       'Neoadjuvant Chemotherapy/Concurrent Chemoradiotherapy ::: Discussion',\n       'Conclusions ::: To the Editor',\n       \"Patients' characteristics and outcome\",\n       'DAA binding to COVID-19 RdRp ::: Results and discussion',\n       'Projections of SARS CoV-2 outcomes assuming remdesivir treatment during early and late symptomatic phases',\n       'Model limitations and discussion',\n       'Treatment ::: RESULTS AND DISCUSSION', 'SUMMARY AND CONCLUSIONS',\n       'Summary and Conclusions', 'SUMMARY AND CONCLUSION',\n       'Results and Discussions',\n       'Conclusions and recommendations for implementing electronic contact tracing solutions',\n       'On the Interpretation of PIPE-Sites Predictions',\n       'Allopathic therapy against COVID-19 ::: Results and discussion',\n       'MM-GBSA study ::: Result and discussion',\n       'Molecular docking ::: Result and discussion',\n       'Pharmacophore model ::: Result and discussion',\n       'A. Possible Interpretations', 'VI. CONCLUSIONS',\n       'Results and Conclusion',\n       'Skeletal muscle injury and myalgia ::: Discussion',\n       'Methods for concentration of enveloped viruses from water matrices ::: Results and discussion',\n       'Persistence of coronavirus in water environments ::: Results and discussion',\n       'Root-Mean-Square Deviation (RMSD) and Interaction Energies ::: Results and Discussion',\n       'AbstrACt',\n       'ER, PgR at diagnosis and clinical response ::: Results and discussion',\n       'Interpretation:', 'Concluding remarks.',\n       'Prospect and Conclusion',\n       'Scope for future research ::: Discussion',\n       'Strengths and limitations ::: Discussion', '4. Discussion ',\n       'Impact of baloxavir treatment on the transmission dynamics of influenza ::: Results and discussion',\n       'Discussion :', 'Discussion 267', 'Discussion and perspectives',\n       'Conclusions and Future Perspectives',\n       'Case study ::: Results and discussion',\n       'CONCLUSION AND FUTURE DIRECTIONS', 'V. DISCUSSION',\n       'ORF8 is a fast-evolving protein in SARS-related CoVs ::: Results and discussion',\n       'Future perspectives ::: Discussion',\n       'Model limitations ::: Discussion',\n       'CONCLUDING REMARKS: A GLIMPSE INTO THE FUTURE',\n       'Concluding remarks: a glimpse into the future',\n       'In vitro evaluation ::: RESULTS AND DISCUSSION',\n       'In vivo efficacy of SQAd/VitE NPs in endotoxemia model ::: RESULTS AND DISCUSSION',\n       'Preparation and characterization SQAd/VitE NPs ::: RESULTS AND DISCUSSION',\n       'Conclusion and prospects', 'Treatment and outcome',\n       'Conclusions and research need for these recommendations',\n       'Comparative analysis of SARS-CoV-2 Mpro, SARS-CoV Mpro and MERS-CoV Mpro at the sequence and structural level ::: Results and discussion',\n       'Comparison of binding affinity of the lead molecules with FDA-approved antiviral drugs ::: Results and discussion',\n       'Conclusions and perspective. ::: Results and Discussion',\n       'Interpretation',\n       'What treatments are effective (including the role of antivirals and steroids)? ::: DISCUSSION',\n       'DISCUSSIONS AND CONCLUSIONS',\n       '3.1. Seasonal Influenza ::: 3. Discussion',\n       '3.3. Pneumonia  ::: 3. Discussion',\n       'Treatment ::: Treatment and Outcome',\n       'Interpretations of findings',\n       'Analysis of top ranked molecules through MD simulations ::: Results and discussions',\n       'Basic Nanoparticle Properties ::: Results and Discussion',\n       'Cryo-Electron Microscopy ::: Results and Discussion',\n       'Lipid Membrane Rigidity ::: Results and Discussion',\n       'Thermal Analysis ::: Results and Discussion',\n       'Clinical management of patients with virus-induced psychosis ::: Discussion and clinical considerations',\n       'Conclusions, limitations and areas of uncertainty',\n       'Infection by SARS‐CoV‐2 ::: DISCUSSION',\n       'IV. DISCUSSION OF GLOBAL RESULTS',\n       'The Paradoxical Effect of ACE2 Modulation in the Outcome of Coronavirus Infections',\n       'Conclusions and Future Directions',\n       '■ CONCLUSIONS AND FUTURE DIRECTIONS', 'Discussion 325',\n       'Pathogenesis and immune response ::: Discussion',\n       'Findings and Discussions on the gene ORF10',\n       'HR skunk works outcomes', 'Chemistry ::: Results and discussion',\n       'Molecular Docking Studies of SARS-CoV nsp14 in complex with dinucleoside 13 ::: Results and discussion',\n       'RNA Methyltransferase Activity Assays ::: Results and discussion',\n       'Pathogenesis ::: DISCUSSION', 'Discussion/conclusion',\n       'Discussion of findings and contrast with literature.',\n       'Conclusion and future perspective:',\n       'Predicting the worst outcome in COVID-19 transplant patients',\n       '2. Results and Discussion', '3. Conclusions', 'diSCUSSion',\n       'Understanding the stabilities of MP-in (1-17) and SARS-CoV-2-MPro complexes ::: Results and discussion',\n       'Patient outcome prediction',\n       'Venous thromboembolic event ::: Cardiovascular complications associated with COVID-19 infection ::: Discussion',\n       'Conclusions and outlook',\n       '3.1. Lessons Learned from SARS ::: 3. Discussion',\n       '3.2. Possible Mechanisms Underlying Comorbid Chronic Diseases, Organ Injuries, and COVID-19 Severity ::: 3. Discussion',\n       '3.3. Conclusion and Outlook ::: 3. Discussion',\n       'Conclusion and Outlook.', 'RdRp ::: Results and discussion',\n       'Spike protein ::: Results and discussion',\n       'Interpretation of the biochemical profile of liver function',\n       'Pathophysiology ::: Discussion',\n       'Laboratory Findings ::: Discussion/Observations ::: Methods',\n       '4. Conclusions and Future Aspects',\n       'Conclusions and Future Aspects',\n       'Explanation for the choice of comparators {6b} ::: Interventions ::: Methods: participants, interventions, and outcomes',\n       'Summary/Conclusion', 'Summary and Discussion', 'Discussion 193',\n       'IN CONCLUSION', 'In Conclusion',\n       '4.1. Summary of Evidence ::: 4. Discussion',\n       'Review and discussion',\n       'The Role of AI toward Optimizing Combinatorial Drug Repurposing ::: Discussion',\n       'Assessment of physiochemical properties, antigenicity, allergenicity and toxicity of designed COVID-19 vaccine candidate ::: Result and Discussion',\n       'IV. CONCLUSION', 'Conclusions and future perspectives',\n       'Conclusion and recommendations',\n       'Estimates of the antigenic regions by pKa shifts – the PROCEEDpKa method ::: Results and discussion',\n       'Free energy of interactions of SARS spike RBD proteins ::: Results and discussion',\n       'Insights to design a more efficient monoclonal antibody ::: Results and discussion',\n       'Physical chemistry properties ::: Results and discussion',\n       'Conclusion and Policy Implications',\n       'Conclusions ::: Authors’ perspective',\n       'MM-PBSA binding free energy ::: Results and discussion',\n       'Inventory management ::: Discussion', 'dISCuSSIon',\n       'Conclusion and future perspectives:', 'Results & discussion',\n       'Antiviral therapy ::: Discussion',\n       'Glucocorticoid ::: Discussion', 'Conclusions.', \"' DISCUSSION\",\n       'Medical interpretation of the result',\n       'MD simulations analysis :::  ::: Result and discussion',\n       'Discussion of studies', 'Conflicts of interest ::: Conclusion',\n       'Pregnancy and breastfeeding ::: Discussion',\n       'Conclusions: time is tissue',\n       'Molecular dynamic simulation analysis ::: Results and discussion',\n       'Mpro potential inhibitors ::: Structure-based virtual screening and molecular docking results ::: Results and discussion',\n       'Timing of urgent surgery ::: Discussion',\n       'Toxicity study ::: Result and discussions',\n       'Hydroxychloroquine treatment ::: Discussion',\n       'Lopinavir/ritonavir-based treatment ::: Discussion',\n       'Ribavirin-based treatment ::: Discussion',\n       'Suggestions for future clinical trial ::: Discussion',\n       'ORF8 is a fast-evolving protein in SARS-CoV-2-related viruses. ::: RESULTS AND DISCUSSION',\n       'Discussion of results',\n       'Discussion of results ::: Discussion and core conclusions',\n       'Implications for IT and business executives ::: Discussion and core conclusions',\n       'Acute cerebrovascular disease ::: Neurologic complications associated with COVID-19 infection ::: Discussion',\n       'Intermolecular interaction studies ::: Results and discussion',\n       '6. Conclusions',\n       'Knowledge About the Spread, Prevention and Treatment of the Disease ::: Discussion',\n       '4. Conclusion',\n       'Pathophysiology and clinical features ::: Discussion',\n       'DISCUSSION: THE USE OF LUNG SURFACTANT FOR PULMONARY BARRIER RESTORATION IN PATIENTS WITH COVID-19 PNEUMONIA',\n       'Discussion: the Use of Lung Surfactant for Pulmonary Barrier Restoration in Patients With COVID-19 Pneumonia',\n       'Docking results ::: Results and discussion',\n       'Laboratory Abnormality and Neurologic Manifestations in COVID-19 ::: Discussion',\n       'Key substrate binding residues contribute to favourable binding free energy to α-ketoamide 13b ::: Results and Discussion',\n       'The α-ketoamide 13b ligand binds with a strong free energy to SARS-CoV-2 Mpro ::: Results and Discussion',\n       'Anti-tussive molecules like δ-viniferin and myricitrin showed higher affinity for the active site of SARS-CoV-2 MPro and other targets ::: Results and discussion',\n       'Binding study repurposes application of anti-influenza and anti-HIV molecule against SARS-CoV-2 infection ::: Results and discussion',\n       'Inter-residue contacts and the structural flexibility is located dominantly in the N-terminal catalytic site harboring beta-barrels ::: Results and discussion',\n       'Discussion 290',\n       'Non-synonymous substitutions and associated amino acid changes ::: Results and Discussion',\n       'Interpretation and Concluding Remarks',\n       'MM/GBSA free binding energy ::: Results and discussion',\n       'Thick description of ensuing discussion and action',\n       '2′-OMTase of SARS-CoV-2 ::: Binding pattern of drug molecules against 3CLpro and 2′-OMTase ::: Results and discussion',\n       'Solvent accessible surface area (SASA) ::: Molecular dynamics (MD) simulation ::: Results and discussion',\n       'T2D Is Correlated with a Higher Risk of All-Cause Mortality and Detrimental Comorbidities in Patients with COVID-19 ::: Results and Discussion',\n       'Analysis and discussion',\n       'MEPVC has appropriate biophysicochemical properties ::: Results and discussion',\n       'Putative molecular mechanisms ::: Discussion',\n       'Safety and limitations ::: Discussion',\n       'Recommendations ::: Monitoring and conduct of anaesthesia ::: Discussion',\n       'Recommendations ::: Neuraxial procedures ::: Discussion',\n       'Recommendations ::: Peripheral nerve block ::: Discussion',\n       'Anticoagulants: heparin and fondaparinux ::: Results and discussion',\n       'Antimalarials ::: Results and discussion',\n       'Glucocorticoids ::: Results and discussion',\n       'Interleukin-1 blockade (anti-IL-1) ::: Results and discussion',\n       'Interleukin-2 inhibition ::: Results and discussion',\n       'Intravenous immunoglobulins / Hyperimmune immunoglobulin ::: Results and discussion',\n       'Other cytokine-targeted therapy ::: Results and discussion',\n       'Other possible complementary nonviral drugs to be used: ACE agonists and statins ::: Results and discussion',\n       'Clinical Pathophysiology and Outcomes',\n       'Discussion and conclusion:',\n       'Functional bridge adaptive immunity in patients with favourable outcomes with COVID 19',\n       'Result and Discussion',\n       '4.1.1. Tegobuvir ::: 4.1. Virus Cell Entry and Replication ::: 4. Discussion',\n       '4.1.2. Siramesine ::: 4.1. Virus Cell Entry and Replication ::: 4. Discussion',\n       '4.2.1. Bemcentinib ::: 4.2. Host Immune Response ::: 4. Discussion',\n       '4.2.2. Sonidegib ::: 4.2. Host Immune Response ::: 4. Discussion',\n       '4.2.3. Itacitinib ::: 4.2. Host Immune Response ::: 4. Discussion',\n       '4.3.2. TG-100801 and Lifitegrast ::: 4.3. Neurological Effects ::: 4. Discussion',\n       'Phthalocyanine ::: 4.4. Decontamination and Self-Disinfection ::: 4. Discussion',\n       'Case presentation and discussion',\n       'Biological implications ::: Discussion',\n       'Distinguishing proteins binding different glycans and sugars ::: Discussion',\n       'Molecular docking of ACE2 ::: Results and discussion',\n       'Teratogenicity ::: Discussion',\n       'Pharmacokinetic properties analysis ::: Results and discussion',\n       'The other side of the coin ::: Discussion',\n       'Dosing recommendations for enhanced safety ::: Results and Discussion',\n       'Early therapy initiation ::: Results and Discussion',\n       'dIsCussIOn', 'Loss of fluid restriction ::: Discussion',\n       'Social Networking Apps (FaceTime and Skype) ::: DISCUSSION',\n       'Concluding Remarks and Future Perspectives',\n       'Findings in context ::: Discussion',\n       'DISCUSSION AND PERSPECTIVES',\n       'CONCLUDING REMARKS AND FUTURE PERSPECTIVES',\n       'Discussion for Gautret et al (n = 36)',\n       'Discussion for Gautret et al (n = 80)',\n       'Discussion for Tang et al (n = 150)',\n       'Conclusions and areas for future work',\n       'Marine drug and mpro interactions ::: Result and discussion',\n       'Conclusion ::: IL-1 blockade ::: Results',\n       'Conclusion ::: IL-6 blockade ::: Results',\n       'Conclusion ::: Low-dose steroids and NSAIDs ::: Results',\n       'Conclusion ::: Tacrolimus ::: Results', 'Overall conclusion'],\n      dtype=object)"},"metadata":{}}]},{"metadata":{"trusted":true,"collapsed":true},"cell_type":"code","source":"claims_data","execution_count":32,"outputs":[{"output_type":"execute_result","execution_count":32,"data":{"text/plain":"      cord_uid      section  \\\n0     01es0zv4     Abstract   \n1     01es0zv4   CONCLUSION   \n2     01es0zv4  CONCLUSION:   \n3     02q9y011     Abstract   \n4     033q671f   Discussion   \n...        ...          ...   \n4776  zsz9xnxt   Discussion   \n4777  zsz9xnxt   Discussion   \n4778  zsz9xnxt   Discussion   \n4779  zsz9xnxt   Discussion   \n4780  zv0ysi8m     Abstract   \n\n                                                   text  \\\n0     coronavirus disease 2019 has become a global p...   \n1     covid-19 is a pandemic with high morbidity and...   \n2     covid-19 is a pandemic with high morbidity and...   \n3     the virus that causes covid-19, sars-cov-2, ha...   \n4     the most common symptoms for sars-cov-2 pneumo...   \n...                                                 ...   \n4776  we demonstrate that mechanically ventilated pa...   \n4777  we demonstrate that mechanically ventilated pa...   \n4778  we demonstrate that mechanically ventilated pa...   \n4779  we demonstrate that mechanically ventilated pa...   \n4780  sars-cov-2 is a novel strain of coronavirus th...   \n\n                                        drug_terms_used  \\\n0     chloroquine,lopinavir,remdesivir,ritonavir,azi...   \n1     chloroquine,lopinavir,remdesivir,ritonavir,azi...   \n2     chloroquine,lopinavir,remdesivir,ritonavir,azi...   \n3                                           amino acids   \n4                                       corticosteroids   \n...                                                 ...   \n4776                                     carbon dioxide   \n4777                                     carbon dioxide   \n4778                                     carbon dioxide   \n4779                                     carbon dioxide   \n4780     chloroquine,favipiravir,remdesivir,chloroquine   \n\n                                                 claims  claim_flag  \n0     it is important to have a knowledge of potenti...         1.0  \n1     caution and careful monitoring should be exerc...         1.0  \n2     caution and careful monitoring should be exerc...         1.0  \n3     although 26% of the amino acids in this sars-c...         1.0  \n4     despite the above limitations, we believe that...         1.0  \n...                                                 ...         ...  \n4776  we demonstrate that mechanically ventilated pa...         1.0  \n4777  in conclusion, we show that higher peep levels...         1.0  \n4778  we suggest using prone position for an extende...         1.0  \n4779  we suggest using prone position for an extende...         1.0  \n4780  this chapter provides a glimpse of advancement...         1.0  \n\n[4781 rows x 6 columns]","text/html":"<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>cord_uid</th>\n      <th>section</th>\n      <th>text</th>\n      <th>drug_terms_used</th>\n      <th>claims</th>\n      <th>claim_flag</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>01es0zv4</td>\n      <td>Abstract</td>\n      <td>coronavirus disease 2019 has become a global p...</td>\n      <td>chloroquine,lopinavir,remdesivir,ritonavir,azi...</td>\n      <td>it is important to have a knowledge of potenti...</td>\n      <td>1.0</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>01es0zv4</td>\n      <td>CONCLUSION</td>\n      <td>covid-19 is a pandemic with high morbidity and...</td>\n      <td>chloroquine,lopinavir,remdesivir,ritonavir,azi...</td>\n      <td>caution and careful monitoring should be exerc...</td>\n      <td>1.0</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>01es0zv4</td>\n      <td>CONCLUSION:</td>\n      <td>covid-19 is a pandemic with high morbidity and...</td>\n      <td>chloroquine,lopinavir,remdesivir,ritonavir,azi...</td>\n      <td>caution and careful monitoring should be exerc...</td>\n      <td>1.0</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>02q9y011</td>\n      <td>Abstract</td>\n      <td>the virus that causes covid-19, sars-cov-2, ha...</td>\n      <td>amino acids</td>\n      <td>although 26% of the amino acids in this sars-c...</td>\n      <td>1.0</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>033q671f</td>\n      <td>Discussion</td>\n      <td>the most common symptoms for sars-cov-2 pneumo...</td>\n      <td>corticosteroids</td>\n      <td>despite the above limitations, we believe that...</td>\n      <td>1.0</td>\n    </tr>\n    <tr>\n      <th>...</th>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n    </tr>\n    <tr>\n      <th>4776</th>\n      <td>zsz9xnxt</td>\n      <td>Discussion</td>\n      <td>we demonstrate that mechanically ventilated pa...</td>\n      <td>carbon dioxide</td>\n      <td>we demonstrate that mechanically ventilated pa...</td>\n      <td>1.0</td>\n    </tr>\n    <tr>\n      <th>4777</th>\n      <td>zsz9xnxt</td>\n      <td>Discussion</td>\n      <td>we demonstrate that mechanically ventilated pa...</td>\n      <td>carbon dioxide</td>\n      <td>in conclusion, we show that higher peep levels...</td>\n      <td>1.0</td>\n    </tr>\n    <tr>\n      <th>4778</th>\n      <td>zsz9xnxt</td>\n      <td>Discussion</td>\n      <td>we demonstrate that mechanically ventilated pa...</td>\n      <td>carbon dioxide</td>\n      <td>we suggest using prone position for an extende...</td>\n      <td>1.0</td>\n    </tr>\n    <tr>\n      <th>4779</th>\n      <td>zsz9xnxt</td>\n      <td>Discussion</td>\n      <td>we demonstrate that mechanically ventilated pa...</td>\n      <td>carbon dioxide</td>\n      <td>we suggest using prone position for an extende...</td>\n      <td>1.0</td>\n    </tr>\n    <tr>\n      <th>4780</th>\n      <td>zv0ysi8m</td>\n      <td>Abstract</td>\n      <td>sars-cov-2 is a novel strain of coronavirus th...</td>\n      <td>chloroquine,favipiravir,remdesivir,chloroquine</td>\n      <td>this chapter provides a glimpse of advancement...</td>\n      <td>1.0</td>\n    </tr>\n  </tbody>\n</table>\n<p>4781 rows × 6 columns</p>\n</div>"},"metadata":{}}]},{"metadata":{"trusted":true,"collapsed":true},"cell_type":"code","source":"no_claims_data","execution_count":48,"outputs":[{"output_type":"execute_result","execution_count":48,"data":{"text/plain":"       cord_uid                                            section  \\\n0      019rcbpg  Potential biological mechanisms of SARS-CoV-2 ...   \n1      019rcbpg  Potential biological mechanisms of SARS-CoV-2 ...   \n2      019rcbpg  Potential biological mechanisms of SARS-CoV-2 ...   \n3      019rcbpg  Potential biological mechanisms of SARS-CoV-2 ...   \n4      019rcbpg  Potential biological mechanisms of SARS-CoV-2 ...   \n...         ...                                                ...   \n19917  zwqci59h                                         Discussion   \n19918  zwqci59h                                         Discussion   \n19919  zwqci59h                                         Discussion   \n19920  zwqci59h                                         Discussion   \n19921  zwqci59h                                         Discussion   \n\n                                                sentence  \\\n0      there are indications in the literature of a n...   \n1      there are indications in the literature of a n...   \n2      there are indications in the literature of a n...   \n3      there are indications in the literature of a n...   \n4      there are indications in the literature of a n...   \n...                                                  ...   \n19917  although recent studies have reported epidemio...   \n19918  although recent studies have reported epidemio...   \n19919  although recent studies have reported epidemio...   \n19920  although recent studies have reported epidemio...   \n19921  although recent studies have reported epidemio...   \n\n                                         drug_terms_used  \\\n0                                              ifn-gamma   \n1                                              ifn-gamma   \n2                                              ifn-gamma   \n3                                              ifn-gamma   \n4                                              ifn-gamma   \n...                                                  ...   \n19917  compro,cyclosporine,methylprednisolone,prednis...   \n19918  compro,cyclosporine,methylprednisolone,prednis...   \n19919  compro,cyclosporine,methylprednisolone,prednis...   \n19920  compro,cyclosporine,methylprednisolone,prednis...   \n19921  compro,cyclosporine,methylprednisolone,prednis...   \n\n                                                  claims  \n0      there are indications in the literature of a n...  \n1      evidence of a variety of neurological symptoms...  \n2      (kotfis, 2020) interestingly two case studies ...  \n3      (moriguchi, 2020) ace2 is a functional recepto...  \n4      (netland et al., 2008) taken together this ind...  \n...                                                  ...  \n19917  2019jyjh09) and the national natural science f...  \n19918       81874091, 81974396, 81772724, and 81672529).  \n19919  conflicts of interest: the authors have nothin...  \n19920  acknowledgments: we thank all the patients and...  \n19921  special thanks to dr. xiao-shan wei for her de...  \n\n[19922 rows x 5 columns]","text/html":"<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>cord_uid</th>\n      <th>section</th>\n      <th>sentence</th>\n      <th>drug_terms_used</th>\n      <th>claims</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>019rcbpg</td>\n      <td>Potential biological mechanisms of SARS-CoV-2 ...</td>\n      <td>there are indications in the literature of a n...</td>\n      <td>ifn-gamma</td>\n      <td>there are indications in the literature of a n...</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>019rcbpg</td>\n      <td>Potential biological mechanisms of SARS-CoV-2 ...</td>\n      <td>there are indications in the literature of a n...</td>\n      <td>ifn-gamma</td>\n      <td>evidence of a variety of neurological symptoms...</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>019rcbpg</td>\n      <td>Potential biological mechanisms of SARS-CoV-2 ...</td>\n      <td>there are indications in the literature of a n...</td>\n      <td>ifn-gamma</td>\n      <td>(kotfis, 2020) interestingly two case studies ...</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>019rcbpg</td>\n      <td>Potential biological mechanisms of SARS-CoV-2 ...</td>\n      <td>there are indications in the literature of a n...</td>\n      <td>ifn-gamma</td>\n      <td>(moriguchi, 2020) ace2 is a functional recepto...</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>019rcbpg</td>\n      <td>Potential biological mechanisms of SARS-CoV-2 ...</td>\n      <td>there are indications in the literature of a n...</td>\n      <td>ifn-gamma</td>\n      <td>(netland et al., 2008) taken together this ind...</td>\n    </tr>\n    <tr>\n      <th>...</th>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n      <td>...</td>\n    </tr>\n    <tr>\n      <th>19917</th>\n      <td>zwqci59h</td>\n      <td>Discussion</td>\n      <td>although recent studies have reported epidemio...</td>\n      <td>compro,cyclosporine,methylprednisolone,prednis...</td>\n      <td>2019jyjh09) and the national natural science f...</td>\n    </tr>\n    <tr>\n      <th>19918</th>\n      <td>zwqci59h</td>\n      <td>Discussion</td>\n      <td>although recent studies have reported epidemio...</td>\n      <td>compro,cyclosporine,methylprednisolone,prednis...</td>\n      <td>81874091, 81974396, 81772724, and 81672529).</td>\n    </tr>\n    <tr>\n      <th>19919</th>\n      <td>zwqci59h</td>\n      <td>Discussion</td>\n      <td>although recent studies have reported epidemio...</td>\n      <td>compro,cyclosporine,methylprednisolone,prednis...</td>\n      <td>conflicts of interest: the authors have nothin...</td>\n    </tr>\n    <tr>\n      <th>19920</th>\n      <td>zwqci59h</td>\n      <td>Discussion</td>\n      <td>although recent studies have reported epidemio...</td>\n      <td>compro,cyclosporine,methylprednisolone,prednis...</td>\n      <td>acknowledgments: we thank all the patients and...</td>\n    </tr>\n    <tr>\n      <th>19921</th>\n      <td>zwqci59h</td>\n      <td>Discussion</td>\n      <td>although recent studies have reported epidemio...</td>\n      <td>compro,cyclosporine,methylprednisolone,prednis...</td>\n      <td>special thanks to dr. xiao-shan wei for her de...</td>\n    </tr>\n  </tbody>\n</table>\n<p>19922 rows × 5 columns</p>\n</div>"},"metadata":{}}]},{"metadata":{"trusted":true},"cell_type":"code","source":"no_claims_data.to_csv('no_claims_tokenized.csv')","execution_count":49,"outputs":[]},{"metadata":{"trusted":true},"cell_type":"code","source":"drug_terms = []\nfor drugs in input_data.drug_terms_used:\n    drug_terms = drug_terms + str(drugs).split(',')\ndrug_terms = list(set(drug_terms))\ndrug_terms.append('acei/arb')\nlen(drug_terms)","execution_count":9,"outputs":[{"output_type":"execute_result","execution_count":9,"data":{"text/plain":"1006"},"metadata":{}}]},{"metadata":{},"cell_type":"markdown","source":"# Replace drug name short forms with full forms"},{"metadata":{"trusted":true},"cell_type":"code","source":"dict = {'hcq':'hydroxychloroquine','cq':'chloroquine','azt':'azithromycin','azi':'azithromycin', 'az':'azithromycin'}\nfor key,value in dict.items():\n    claims_data['claims'] = [t.lower().replace(key,value) for t in claims_data.claims]\n    no_claims_data['claims'] = [t.lower().replace(key,value) for t in no_claims_data.claims]","execution_count":28,"outputs":[]},{"metadata":{},"cell_type":"markdown","source":"# Append sentences from papers with no claims to claim sentences "},{"metadata":{"trusted":true},"cell_type":"code","source":"claims_data = claims_data.append(no_claims_data).reset_index(drop=True)","execution_count":29,"outputs":[]},{"metadata":{"trusted":true},"cell_type":"code","source":"del(no_claims_data)","execution_count":30,"outputs":[]},{"metadata":{},"cell_type":"markdown","source":"# Filter to sentences that mention drug names"},{"metadata":{"trusted":true},"cell_type":"code","source":"sentences_to_keep = [any([True for d in drug_terms if d in c]) for c in claims_data.claims]\nclaims_data = claims_data[sentences_to_keep].reset_index(drop=True)\nprint(len(claims_data))\n\nclaims_data['drug_terms_mention'] = [[d for d in drug_terms if d in c] for c in claims_data.claims]","execution_count":58,"outputs":[{"output_type":"stream","text":"4643\n","name":"stdout"}]},{"metadata":{"trusted":true},"cell_type":"code","source":"print('No of papers being compared:',claims_data.cord_uid.nunique())","execution_count":59,"outputs":[{"output_type":"stream","text":"No of papers being compared: 1383\n","name":"stdout"}]},{"metadata":{},"cell_type":"markdown","source":"# Pair similar claims"},{"metadata":{"trusted":true},"cell_type":"code","source":"paper_pairs = list(combinations(claims_data.index,2))\npaper_pairs_filt = []\nfor i,j in tqdm(paper_pairs):\n    if claims_data.cord_uid[i]!=claims_data.cord_uid[j]:\n        if any(d1 in claims_data.drug_terms_mention[i] for d1 in claims_data.drug_terms_mention[j]):\n            paper_pairs_filt.append((i,j))\nlen(paper_pairs_filt)","execution_count":61,"outputs":[{"output_type":"stream","text":"100%|██████████| 10776403/10776403 [29:28<00:00, 6095.01it/s]\n","name":"stderr"},{"output_type":"execute_result","execution_count":61,"data":{"text/plain":"721705"},"metadata":{}}]},{"metadata":{"trusted":true},"cell_type":"code","source":"claims_data['w2vVector'] = [nlp(c).vector.reshape(1,-1) for c in claims_data.claims]","execution_count":63,"outputs":[]},{"metadata":{"trusted":true},"cell_type":"code","source":"dict = {}\nk = 0\n\njit(nopython=True, parallel=True)\n\nfor i,j in tqdm(paper_pairs_filt):\n    #cos_sim = cosine_similarity(np.array(claims_data.w2vVector[i]).reshape(1,-1),np.array(claims_data.w2vVector[j]).reshape(1,-1))[0][0]\n    cos_sim = cosine_similarity(claims_data.w2vVector[i],claims_data.w2vVector[j])[0][0]\n    if cos_sim>=0.5:\n        dict[k] = {'paper1_cord_uid':claims_data.cord_uid[i],\\\n                    'paper2_cord_uid':claims_data.cord_uid[j],\\\n                    'text1':claims_data.claims[i],\\\n                    'text2':claims_data.claims[j],\\\n                    'similarity_score':cos_sim,\\\n                    'drugs1':claims_data.drug_terms_used[i],\\\n                    'drugs2':claims_data.drug_terms_used[j]}\n        k = k + 1\nclaims_similarity = pd.DataFrame.from_dict(dict, \"index\")","execution_count":66,"outputs":[{"output_type":"stream","text":"100%|██████████| 721705/721705 [08:58<00:00, 1338.99it/s]\n","name":"stderr"}]},{"metadata":{"trusted":true},"cell_type":"code","source":"print(len(claims_similarity))","execution_count":67,"outputs":[{"output_type":"stream","text":"650019\n","name":"stdout"}]},{"metadata":{"trusted":true},"cell_type":"code","source":"print(claims_similarity.paper1_cord_uid.nunique())\nprint(claims_similarity.paper2_cord_uid.nunique())","execution_count":68,"outputs":[{"output_type":"stream","text":"1288\n1230\n","name":"stdout"}]},{"metadata":{},"cell_type":"markdown","source":"# Add title & publish time fields"},{"metadata":{"trusted":true},"cell_type":"code","source":"claims_similarity = pd.merge(claims_similarity,metadata,how='inner',\\\n                           left_on = 'paper1_cord_uid',\\\n                          right_on = 'cord_uid')\ncols_rename = {'title':'title1','publish_time':'publish_time1'}\nclaims_similarity.rename(columns = cols_rename,inplace=True)\n\nclaims_similarity = pd.merge(claims_similarity,metadata,how='inner',\\\n                           left_on = 'paper2_cord_uid',\\\n                          right_on = 'cord_uid')\ncols_rename = {'title':'title2','publish_time':'publish_time2'}\nclaims_similarity.rename(columns = cols_rename,inplace=True)\n\nprint(len(claims_similarity))","execution_count":69,"outputs":[{"output_type":"stream","text":"660964\n","name":"stdout"}]},{"metadata":{"trusted":true},"cell_type":"code","source":"claims_similarity = claims_similarity.drop(columns=['cord_uid_x','cord_uid_y'])","execution_count":70,"outputs":[]},{"metadata":{"trusted":true},"cell_type":"code","source":"claims_similarity.to_csv('drug_individual_claims_filtered.csv')","execution_count":71,"outputs":[]},{"metadata":{"trusted":true},"cell_type":"code","source":"claims_similarity.to_json('drug_individual_claims_filtered.json')","execution_count":null,"outputs":[]}],"metadata":{"kernelspec":{"language":"python","display_name":"Python 3","name":"python3"},"language_info":{"name":"python","version":"3.7.6","mimetype":"text/x-python","codemirror_mode":{"name":"ipython","version":3},"pygments_lexer":"ipython3","nbconvert_exporter":"python","file_extension":".py"}},"nbformat":4,"nbformat_minor":4}